Concepedia

Lillian Skidmore

LS

5

Publications

382

Citations

5

H-Index

2011

Active since

Affiliations

Ambrx (United States)(Current)

Lillian Skidmore is an author at Ambrx (United States) specializing in protein engineering, natural sciences, and drug discovery.

Top concepts

Publications per year

2011–2024

5

Publications

5

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

James Mu, Jason Pinkstaff, Zhihua Li et al. · Diabetes · 2011 · 158 citations · Full text

, , +19

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Lillian Skidmore, Sukumar Sakamuri, Nick Knudsen et al. · Molecular Cancer Therapeutics · 2020 · 151 citations

Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers

Robin Humphreys, Jessica Kirtely, Amha Hewit et al. · Cancer Research · 2015 · 33 citations

, , +25

Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

Prathap Nagaraja Shastri, Jingjing Zhu, Lillian Skidmore et al. · Molecular Cancer Therapeutics · 2020 · 29 citations

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Lillian Skidmore, David Mills, Ji Young Kim et al. · Molecular Cancer Therapeutics · 2024 · 11 citations · Full text

Rows per page

1–5 of 5